Endothelin receptor antagonist

Results: 12



#Item
1Clinical Commissioning Policy: Clinical Commissioning Policy: National policy for targeted

Clinical Commissioning Policy: Clinical Commissioning Policy: National policy for targeted

Add to Reading List

Source URL: www.england.nhs.uk

Language: English - Date: 2014-08-12 08:06:05
2Kwartaalbericht 4e kwartaalNovember 2005  Contents

Kwartaalbericht 4e kwartaalNovember 2005 Contents

Add to Reading List

Source URL: www.lareb.nl

Language: English
3ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1  1.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1.

Add to Reading List

Source URL: www.ema.europa.eu

Language: English
4Better understanding of blood vessel constrictor needed to harness its power for patients

Better understanding of blood vessel constrictor needed to harness its power for patients

Add to Reading List

Source URL: phys.org

Language: English - Date: 2015-03-04 03:05:36
5Bosentan (Tracleer®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS BOSENTAN?

Bosentan (Tracleer®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS BOSENTAN?

Add to Reading List

Source URL: www.phassociation.org

Language: English - Date: 2013-12-03 14:16:08
6Ambrisentan (Letairis®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS AMBRISENTAN?

Ambrisentan (Letairis®) Issued by PHA’s Scientific Leadership Council Information is based on the United States Food and Drug Administration drug labeling Last Updated November[removed]WHAT IS AMBRISENTAN?

Add to Reading List

Source URL: www.phassociation.org

Language: English - Date: 2013-12-03 14:16:08
7TRACLEER® [bosentan[removed]mg and 125 mg film-coated tablets Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury, and 2) potential damage to a fetus.

TRACLEER® [bosentan[removed]mg and 125 mg film-coated tablets Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury, and 2) potential damage to a fetus.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:51:02
8TRACLEER® [bosentan[removed]mg and 125 mg film-coated tablets Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury and 2) potential damage to a fetus.

TRACLEER® [bosentan[removed]mg and 125 mg film-coated tablets Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury and 2) potential damage to a fetus.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:51:02
9John Teerlink: Renaissance man and leader in heart failure research

John Teerlink: Renaissance man and leader in heart failure research

Add to Reading List

Source URL: download.thelancet.com

Language: English
10Microsoft PowerPoint - PAR IC 2007 Flyer 2

Microsoft PowerPoint - PAR IC 2007 Flyer 2

Add to Reading List

Source URL: patients.thoracic.org

Language: English - Date: 2014-06-03 14:44:30